{
  "abstract": "Background and Importance According to WHO, antimicrobial resistance is one of the top public health threats world- wide. Antimicrobial resistance is caused mainly by the overuse and/or misuse of antimicrobials, leading to an ongoing need to develop novel antibiotics. 1 Gepotidacin is a first-in-class oral antibiotic that was approved recently by the FDA on 25 March 2025 to treat uncomplicated urinary tract infections (UTIs).2 While several clinical trials demonstrate promising results related to gepotidacin efficacy and safety, further analysis is needed to assess its benefits, tolerability, and resistance risk in order to improve treatment outcomes and support antimicrobial stewardship.Aim and Objectives This study aims to review the clinical literature related to gepotidacin with a focus on it evaluating its spectrum of activity, tolerability, efficacy, safety. The study objectives include analysing gepotidacin’s clinical outcomes, assessing its effectiveness against resistant pathogens, and identifying its future directions for its therapeutic use.Material and Methods A comprehensive literature review was conducted across five electronic databases: EBSCOhost, ProQuest, PubMed, Science Direct and Google Scholar. The studies included were those involving healthy volunteers or patients and published in the English language in the past 15 years, from 2010 to 2025. The content of the selected publications related to the use of gepotidacin were reviewed by two reviewers to confirm compliance with the inclusion criteria followed by data extraction.Results In total, 18 clinical studies were identified that investigated gepotidacin efficacy in human healthy volunteers or patients. These studies reported gepotidacin’s tolerability, promising pharmacokinetic profile and lack of major drug-drug interactions. In patients with hepatic or renal impairment, minimal dose adjustments were required. In addition to the efficacy of gepotidacin in managing UTIs, its potential for treating drug-resistant gonorrhoea and Gram-positive acute bacterial skin was reported.Conclusion and Relevance Beyond its effectiveness in treating UTI, gepotidacin is a promising antibiotic with the potential in managing drug-resistant infections. Gepotidacin opens the door for a new generation of antibiotics with novel mechanism of action capable of addressing antimicrobial resistance.References and/or Acknowledgements 1. World Health Organization. (2023, November 21). Antimicrobial resistance [Fact sheet]. https://www.who.int/newsroom/fact-sheets/detail/antimicrobial-resistance.2. U.S. Food and Drug Administration. (2025). Novel drug approvals 2025. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Higher College of Technology, Faculty of Health Sciences, Abu Dhabi, United Arab Emirates"
      ],
      "name": "M Aburahma"
    },
    {
      "affiliations": [
        "Higher College of Technology, Faculty of Health Sciences, Dubai, United Arab Emirates"
      ],
      "name": "N Hashad"
    }
  ],
  "title": "6ER-017 Gepotidacin, a newly first-in-class FDA approved antibiotic for treatment of uncomplicated urinary tract infection",
  "uid": "fbc40b98-0f56-533d-93cd-dab1421d5bf0"
}